Celgene reports positive data from Phase Ib study of GED-0301 for Crohn ’s disease

US-based Celgene's Swiss subsidiary Celgene International has reported positive data from its exploratory Phase Ib CD-001 study of GED-0301 (mongersen) to treat active Crohn ’s disease.

Source: Drug Development Technology - October 16, 2016 Category: Pharmaceuticals Source Type: news